2-溴-5-甲氧基苯硫醇 | 13993-51-6

• 物质功能分类: 有机原料 - 腈类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 中文名称: 2-溴-5-甲氧基苯硫醇
• 英文名称: 2-bromo-5-methoxybenzenethiol
• CAS: 13993-51-6
• 化学式: C₇H₇BrOS
• 分子量: 219.102
• InChiKey: OPVIAUGHOYNQLE-UHFFFAOYSA-N

物化性质

• 沸点：
  89-90 °C(Press: 0.15 Torr)
• 密度：
  1.540±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  10.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-5-甲氧基苯硫醇 在 titanium(IV) isopropylate 、 三乙基硅烷 、 叔丁基过氧化氢 、 氢氧化钾 、 正丁基锂 、 D-(-)-酒石酸二乙酯 、 potassium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 219.0h， 生成 4-(4-methoxy-2-(S)-methylsulfinylphenyl)piperidine
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  2-溴-5-甲氧基苯酚 在 三乙烯二胺 、 氢氧化钾 、 N,N-二乙基苯胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 2-溴-5-甲氧基苯硫醇
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i

文献信息

• 10.beta.,11.beta.-bridged steroids
  申请人：Schering Aktiengesellschaft

  公开号：US05093507A1

  公开（公告）日：1992-03-03

  10.beta.,11.beta.-bridged steroids of Formula I ##STR1## wherein R.sup.1 is H or methyl; R.sup.2 is H, a cyanide residue, a heteroaryl residue, a straight-chain or branched aliphatic, e.g., alkyl group of up to 20 carbon atoms, optionally exhibiting double or triple bonds and, if desired, being substituted by one or several oxo groups, a C.sub.4-7 cycloalkyl or C.sub.4-7 cycloalkenyl group, an OR.sup.3 --, SR.sup.3 --, --OSO.sub.2 --R.sup.11 -- group wherein R.sup.11 means a perfluroinated C.sub.1 -C.sub.4 -alkyl group or an NR.sup.3 R.sup.4 -group wherein R.sup.3 means an H atom or C.sub.1 -C.sub.8 -alkyl residue, R.sup.4 means R.sup.3, a cyanide or a C.sub.1 -C.sub.10 -acyl residue, or R.sup.3 and R.sup.4 jointly with the inclusion of N means of 5- or 6-membered heterocyclic ring wherein the ring can additionally contain a further hetero atom N, O, or S, or a 4-cyano-, 4-methoxy- or 4-dimethylamino-substituted phenyl group, A and B either mean jointly a further bond between C4 and C5, or A is an .alpha.-hydroxy group and B is H, X is a keto or oxime group, and Z is a pentagonal or hexagonal ring residue which is optionally substituted and optionally unsaturated, or pharmaceutically compatible acid additional salts thereof which possess antigestagen and antiglucocorticoid properties.

  在公式I中，R.sup.1为H或甲基；R.sup.2为H、氰基残基、杂环芳基残基、直链或支链脂肪族，例如最多含有20个碳原子的烷基基团，可选择地具有双键或三键，如有需要，可以被一个或几个氧基取代，也可以是C.sub.4-7环烷基或C.sub.4-7环烯基基团，或者是一个OR.sup.3 --、SR.sup.3 --、--OSO.sub.2 --R.sup.11 --基团，其中R.sup.11表示全氟化的C.sub.1-C.sub.4-烷基基团或一个NR.sup.3 R.sup.4 -基团，其中R.sup.3表示氢原子或C.sub.1-C.sub.8-烷基残基，R.sup.4表示R.sup.3、氰基或C.sub.1-C.sub.10-酰基残基，或者R.sup.3和R.sup.4共同包括N的5-或6-成员杂环，其中该环还可以额外含有另一个杂原子N、O或S，或者是一个4-氰基、4-甲氧基或4-二甲基氨基取代的苯基基团，A和B要么共同表示C4和C5之间的进一步键合，要么A是一个α-羟基，B是H，X是一个酮基或肟基团，Z是一个五角形或六角形环残基，可以选择地被取代和选择地不饱和，或其药学上兼容的酸盐，具有抗孕激素和抗糖皮质激素特性。
• A New Approach to Rapid Parallel Development of Four Neurokinin Antagonists. Part 4. Synthesis of ZD2249 Methoxy Sulfoxide
  作者：Sharon A. Bowden、J. Nigel Burke、Fiona Gray、Steven McKown、Jonathan D. Moseley、William O. Moss、Paul M. Murray、Matthew J. Welham、Maureen J. Young

  DOI：10.1021/op030039z

  日期：2004.1.1

  The manufacture of ZD2249 methoxy sulfoxide (1) using a new project approach is described. Research department processes were scaled up to 100 L if process safety and robustness were not compromised; other factors were treated according to the new approach. Using this strategy, we were able to manufacture a key intermediate on sufficient scale to support delivery of 1 kg quantities of bulk drug within

  描述了使用新的项目方法制造 ZD2249 甲氧基亚砜 (1)。如果过程安全性和稳健性不受影响，研究部门的过程可扩大到 100 L；其他因素按照新方法处理。使用这种策略，我们能够在实验室工作开始后的 6 个月内制造出足够规模的关键中间体，以支持交付 1 公斤的原料药。
• 11.beta.-aryl-4-estrenes, process for their production as well as their
  申请人：Schering Aktiengesellschaft

  公开号：US05728689A1

  公开（公告）日：1998-03-17

  A method of inducing an antigestagenic effect by the administration of compounds of formula I: ##STR1## wherein, substituents are as defined in the specification.

  通过给予式I化合物的管理来诱导抗孕激素效应的方法：##STR1##其中，取代基如规范中定义。
• [EN] PURINE DERIVATIVES SUITABLE FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE PURINE APPROPRIÉS POUR LE TRAITEMENT DU CANCER, DES MALADIES AUTO-IMMUNES ET INFLAMMATOIRES
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2009136144A1

  公开（公告）日：2009-11-12

  The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, L1, Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

  本发明提供了一种化合物，该化合物是（a）公式（I）的氨基酸衍生物或其互变异构体，或（b）其药学上可接受的盐，N-氧化物，水合物或溶剂化物：其中R1，R2，L1，Het，A，x，y和W如本文所定义。这些化合物在治疗由HSP90介导的疾病中有用。
• 2-Pyridinyl-phenyl-sulphinyl-and-phenyl-thio-benzimidazoles having
  申请人：Fisons plc

  公开号：US04900751A1

  公开（公告）日：1990-02-13

  Compounds of formula I, ##STR1## in which A is a 5 or 6 membered, fully unsaturated, carbocyclic or heterocyclic ring, B is a 5 or 6 membered, fully unsaturated, nitrogen containing heterocyclic ring, X is NR.sub.19, O or S, R.sub.19 is hydrogen or alkyl optionally substituted by --OCOR, n is 0 or 1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 have various significances, R.sub.1 and R.sub.2, are hydrogen or alkyl or together with the ring carbon atoms to which they are attached, form a benzene or pyridine ring, which ring carries substituents R.sub.15, R.sub.16, R.sub.17 and R.sub.18, R.sub.15, R.sub.16, R.sub.17 and R.sub.18, have various significances, with certain provisos are described. Processes for making the compounds and pharmaceutical formulations containing them, e.g. for the treatment of conditions including excess gastric acid secretion, are also described.

  化合物的式子为I，其中A是一个5或6成员的，完全不饱和的，碳环或杂环，B是一个5或6成员的，完全不饱和的，含氮的杂环，X是NR.sub.19，O或S，R.sub.19是氢或烷基，可以被-OCOR取代，n为0或1，R.sub.3，R.sub.4，R.sub.5，R.sub.6，R.sub.7，R.sub.8，R.sub.9和R.sub.10具有不同的意义，R.sub.1和R.sub.2是氢或烷基，或与它们附着的环碳原子一起形成苯环或吡啶环，该环携带取代基R.sub.15，R.sub.16，R.sub.17和R.sub.18，R.sub.15，R.sub.16，R.sub.17和R.sub.18具有不同的意义，在某些条件下进行描述。还描述了制备该化合物和含有它们的制药配方，例如用于治疗包括胃酸过多在内的疾病。